Heart Failure With Preserved Ejection Fraction Clinical Trials in Ann Arbor, Michigan
4 studies are recruiting for heart failure with preserved ejection fraction in Ann Arbor, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…
- Stage
- Phase 3
- Ages
- 18 to 99
- Site
- University of Michigan Health System, Dominos Farms, Ann Arbor, Michigan
- Locations
- 657 in total
- Run by
- Amgen
-
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Michigan, Ann Arbor, Michigan
- Locations
- 105 in total
- Run by
- Impulse Dynamics
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria ma…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Michigan, Ann Arbor, Michigan
- Run by
- University of Michigan
-
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will no…
- Stage
- Phase 3
- Ages
- 50 to 99
- Site
- University of Michigan Medical Center, Ann Arbor, Michigan
- Locations
- 78 in total
- Run by
- Uppsala University
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.